Vodobatinib| ChemScene
Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research[2].In Vitro: In Ba/F3 cells expressing BCR-ABL1, BCR-ABL1L248V, BCR-ABL1Y253H, or BCR-ABL1E255V, Vodobatinib (K0706; 0-2000 nM) treatment shows potent inhibition of BCR-ABL1 tyrosine autophosphorylation.
Trivial name | Vodobatinib |
Catalog Number | CS-0138668 |
Alternative Name(s) | K0706 |
Molecular Formula | 453.92 |
CAS# | 1388803-90-4 |
Purity | >98% |
Condensed Formula | C27H20ClN3O2 |
Size | 50mg |
Supplier Page | www.chemscene.com/1388803-90-4.html |